AACR logo

More articles from Cancer Therapeutics Insights

Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma–Induced Immune Suppression
Xiaoxia Sun, Qiangjun Sui, Cai Zhang, Zhigang Tian, Jian Zhang

Molecular Cancer Therapeutics Dec 2013, 12 (12) 2885-2896; DOI: 10.1158/1535-7163.MCT-12-1087
Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Anutosh Ganguly, Hailing Yang, Hong Zhang, Fernando Cabral, Kamala D. Patel

Molecular Cancer Therapeutics Dec 2013, 12 (12) 2837-2846; DOI: 10.1158/1535-7163.MCT-13-0401
Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo
Deanna M. Janzen, Daniel Y. Paik, Miguel A. Rosales, Brian Yep, Donghui Cheng, Owen N. Witte, Huseyin Kayadibi, Christopher M. Ryan, Michael E. Jung, Kym Faull, Sanaz Memarzadeh

Molecular Cancer Therapeutics Dec 2013, 12 (12) 2917-2928; DOI: 10.1158/1535-7163.MCT-13-0572
Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth
Marc A. Becker, Thahir Farzan, Sean C. Harrington, James W. Krempski, S. John Weroha, Xiaonan Hou, Kimberly R. Kalli, Tai W. Wong, Paul Haluska

Molecular Cancer Therapeutics Dec 2013, 12 (12) 2909-2916; DOI: 10.1158/1535-7163.MCT-13-0547
PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy
Jeremy P.H. Chow, Wing Yu Man, Mao Mao, Han Chen, Florence Cheung, John Nicholls, Sai Wah Tsao, Maria Li Lung, Randy Y.C. Poon

Molecular Cancer Therapeutics Nov 2013, 12 (11) 2517-2528; DOI: 10.1158/1535-7163.MCT-13-0010
Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
Keith M. Giles, Felicity C. Kalinowski, Patrick A. Candy, Michael R. Epis, Priscilla M. Zhang, Andrew D. Redfern, Lisa M. Stuart, Gregory J. Goodall, Peter J. Leedman

Molecular Cancer Therapeutics Nov 2013, 12 (11) 2541-2558; DOI: 10.1158/1535-7163.MCT-13-0170
Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide
Hau-Lun Huang, Hui-Ping Hsu, Shu-Chu Shieh, Yung-Sheng Chang, Wei-Ching Chen, Chien-Yu Cho, Chiao-Fang Teng, Ih-Jen Su, Wen-Chun Hung, Ming-Derg Lai

Molecular Cancer Therapeutics Nov 2013, 12 (11) 2505-2516; DOI: 10.1158/1535-7163.MCT-12-0863
Hsp90 Inhibitors Promote p53-Dependent Apoptosis through PUMA and Bax
Kan He, Xingnan Zheng, Lin Zhang, Jian Yu

Molecular Cancer Therapeutics Nov 2013, 12 (11) 2559-2568; DOI: 10.1158/1535-7163.MCT-13-0284
Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide
Marcus Eich, Wynand Paul Roos, Teodora Nikolova, Bernd Kaina

Molecular Cancer Therapeutics Nov 2013, 12 (11) 2529-2540; DOI: 10.1158/1535-7163.MCT-13-0136
The Cannabinoid WIN 55,212-2 Decreases Specificity Protein Transcription Factors and the Oncogenic Cap Protein eIF4E in Colon Cancer Cells
Sandeep Sreevalsan, Stephen Safe

Molecular Cancer Therapeutics Nov 2013, 12 (11) 2483-2493; DOI: 10.1158/1535-7163.MCT-13-0486

Main menu

User menu

Search

More articles from Cancer Therapeutics Insights

Pages

Articles

Info for

About MCT